WO2001039758A3 - Verfahren mit thalidomid und antiinflammatorisches zitokin zur behandlung und/oder prophylaxe von il-12-bedingten erkrankungen - Google Patents

Verfahren mit thalidomid und antiinflammatorisches zitokin zur behandlung und/oder prophylaxe von il-12-bedingten erkrankungen Download PDF

Info

Publication number
WO2001039758A3
WO2001039758A3 PCT/EP2000/011179 EP0011179W WO0139758A3 WO 2001039758 A3 WO2001039758 A3 WO 2001039758A3 EP 0011179 W EP0011179 W EP 0011179W WO 0139758 A3 WO0139758 A3 WO 0139758A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
thalidomide
diseases caused
prophylaxis
inflammatory cytokine
Prior art date
Application number
PCT/EP2000/011179
Other languages
English (en)
French (fr)
Other versions
WO2001039758A2 (de
Inventor
Tieno Germann
Stefanie Frosch
Original Assignee
Gruenenthal Gmbh
Tieno Germann
Stefanie Frosch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh, Tieno Germann, Stefanie Frosch filed Critical Gruenenthal Gmbh
Priority to AU13938/01A priority Critical patent/AU1393801A/en
Publication of WO2001039758A2 publication Critical patent/WO2001039758A2/de
Publication of WO2001039758A3 publication Critical patent/WO2001039758A3/de
Priority to US10/156,771 priority patent/US20030021763A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

Es wird eine Kombinationstherapie zur Behandlung von Erkrankungen, die durch die Bildung des entzündungsfördernden Zytokins IL-12 hervorgerufen werden, beschrieben, wobei gleichzeitig eine Thalidomidverbindung und ein antiinflammatorisches Zytokin appliziert werden.
PCT/EP2000/011179 1999-11-29 2000-11-11 Verfahren mit thalidomid und antiinflammatorisches zitokin zur behandlung und/oder prophylaxe von il-12-bedingten erkrankungen WO2001039758A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU13938/01A AU1393801A (en) 1999-11-29 2000-11-11 Method for the treatment and/or prophylaxis of diseases caused by il-12
US10/156,771 US20030021763A1 (en) 1999-11-29 2002-05-29 Method for the treatment and/or prophylaxis of diseases caused by IL-12

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957342.5 1999-11-29
DE19957342A DE19957342A1 (de) 1999-11-29 1999-11-29 Verfahren zur Behandlung und/oder Prophylaxe von IL-12-bedingten Erkrankungen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/156,771 Continuation US20030021763A1 (en) 1999-11-29 2002-05-29 Method for the treatment and/or prophylaxis of diseases caused by IL-12

Publications (2)

Publication Number Publication Date
WO2001039758A2 WO2001039758A2 (de) 2001-06-07
WO2001039758A3 true WO2001039758A3 (de) 2002-03-28

Family

ID=7930686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011179 WO2001039758A2 (de) 1999-11-29 2000-11-11 Verfahren mit thalidomid und antiinflammatorisches zitokin zur behandlung und/oder prophylaxe von il-12-bedingten erkrankungen

Country Status (4)

Country Link
US (1) US20030021763A1 (de)
AU (1) AU1393801A (de)
DE (1) DE19957342A1 (de)
WO (1) WO2001039758A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
DE10049481A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte C-Cyclohexylmethylamin-Derivate
DE10163595A1 (de) 2001-12-21 2003-08-07 Gruenenthal Gmbh In 3-Position heterocyclisch substituierte Piperidin-2,6-dione
EP1737453A4 (de) * 2004-03-22 2008-11-26 Celgene Corp Verfahren zur verwendung immunmodulatorischer verbindungen und diese enthaltende zusammensetzungen zur behandlung und versorgung von hautkrankheiten oder störungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040838A1 (de) * 1999-03-31 2000-10-04 Grünenthal GmbH Stabile wässrige Lösung von EM 12

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2438297A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
AU3469400A (en) * 1999-01-05 2000-07-24 Clarence C. Lee Pharmaceutical compositions for treatment of diseased tissues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040838A1 (de) * 1999-03-31 2000-10-04 Grünenthal GmbH Stabile wässrige Lösung von EM 12

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GROSS, WOLFGANG L.: "New concepts in treatment protocols for severe systemic vasculitis", CURR. OPIN. RHEUMATOL. (1999), 11(1), 41-46, XP001033400 *
RUSSELL, ANDREW I. ET AL: "Potential new therapeutic options in Behcet's syndrome", BIODRUGS (2001), 15(1), 25-35, XP001033419 *
TEBBE B. ET AL: "[Therapeutic aspects of cutaneous lupus erythematosus]. HEUTIGE THERAPEUTISCHE ASPEKTE BEIM KUTANEN LUPUS ERYTHEMATODES.", DERMATOLOGISCHE MONATSSCHRIFT, (1992) 178/3 (99-104)., XP001033514 *
WEILBACH F.X. ET AL: "Disease modifying treatments for multiple sclerosis: What is on the horizon?.", CNS DRUGS, (1999) 11/2 (133-157)., XP001033418 *

Also Published As

Publication number Publication date
WO2001039758A2 (de) 2001-06-07
AU1393801A (en) 2001-06-12
US20030021763A1 (en) 2003-01-30
DE19957342A1 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
NO20040936L (no) Plaster for behandling av dysfunksjoner og forstyrrelser ved neglevekst.
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
HUP0102295A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
WO2004037205A3 (en) LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
WO2003037886A3 (en) Heteroaromatic carboxamide derivatives for the treatment of inflammation
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002329022A1 (en) Method and pharmaceutical composition for treating inflammation
HUP0102367A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
WO2003088903A3 (en) Compounds, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2001285747A1 (en) Method for the treatment of tobacco
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
WO2004006865A3 (en) Compounds, compositions, and methods
WO2004032840A3 (en) Compounds, compositions, and methods
AU2001290961A1 (en) Method for topical treatment of anthralin-responsive dermatological disorders
WO2001039758A3 (de) Verfahren mit thalidomid und antiinflammatorisches zitokin zur behandlung und/oder prophylaxe von il-12-bedingten erkrankungen
WO2001057042A3 (de) 4-pyridyl- und 2,4-pyrimidinyl-substituierte pyrrolderivate und ihre anwendung in der pharmazie
AU7088100A (en) Method employing imiquimod cream for treatment of topical sarcoidosis on equine
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2001041755A3 (en) Topical compositions comprising thalidomide for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10156771

Country of ref document: US

122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)